BiotechTube
Home/Takeda Pharmaceutical/Andrew Plump
AP

Andrew Plump

President, Research & Development

Takeda Pharmaceutical

Therapeutic Areas

OncologyRare DiseasesNeuroscienceGastroenterology

Takeda Pharmaceutical Pipeline

DrugIndicationPhase
Entyvio (vedolizumab)Inflammatory Bowel DiseaseCommercial
Ninlaro (ixazomib)Multiple MyelomaCommercial
Vyvanse (lisdexamfetamine)ADHDCommercial
Adcetris (brentuximab vedotin)LymphomasCommercial
Takecab (vonoprazan)Acid-related disordersCommercial
TAK-981Solid tumorsPhase 1/2
TAK-676Solid tumorsPhase 1
TAK-573Solid tumorsPhase 1

Leadership Team at Takeda Pharmaceutical

CW
Christophe Weber
President and Chief Executive Officer
CS
Costa Saroukos
Chief Financial Officer
JK
Julie Kim
Chief Medical Officer
RS
Ramona Sequeira
President, United States Business Unit
GP
Giles Platford
President, Growth & Emerging Markets Business Unit
DE
Dirk Ehmann
President, Europe Business Unit
TA
Takeshi Aramaki
President, Japan Business Unit
View full Takeda Pharmaceutical profile